Personalised cancer medicine start-up Curesponse has become the latest MedTech company to move in at the Innovation Gateway at The London Cancer Hub in Sutton, south London.

Members of the ICR’s Discovery Club gathered at The Royal Society to hear about our new five-year research strategy and to mark two years since the opening of our pioneering Centre for Cancer Drug Discovery.

The centre will focus on ‘targeted protein degradation’ – one of the hottest and most promising areas in drug discovery. Scientists aim to hijack normal process of protein destruction to wipe out cancer proteins that traditional targeted drugs cannot block.